Literature DB >> 29141716

Hansen's Disease and Rheumatoid Arthritis Crossover of Clinical Symptoms: A Case Series of 18 Patients in the United States.

Sarah M Labuda1, John S Schieffelin1, Jeffrey G Shaffer2, Barbara M Stryjewska3.   

Abstract

Hansen's Disease (HD) is a rare, chronic granulomatous infection of the skin and peripheral nerves caused by the noncultivable organism Mycobacterium leprae. Arthritis is the third most common symptom of HD. Subjects with both confirmed HD on skin biopsy and chronic arthritis were identified at the National Hansen's Disease Program (NHDP). We conducted a series of medical chart reviews and extracted and logged personally deidentified data into a database and carried out descriptive analyses. Eighteen of 261 subjects presented to the NDHP with both HD and chronic arthritis between 2001 and 2015. Among these, 16 were male, 16 were white, and 15 were residents of Louisiana. The median age at diagnosis of HD was 67 years. Ten of these subjects were diagnosed with borderline lepromatous leprosy, seven were diagnosed with lepromatous, and one was diagnosed with borderline tuberculoid leprosy. Patients were symptomatic with arthritis for a median of 5.3 years before HD diagnosis. Sixty-two percent of patients (11) were diagnosed with rheumatoid arthritis (RA) before HD diagnosis, and 10 of which were seronegative RA. Hands, feet, wrists, and elbows were most commonly reported as affected joints. Over half of the patients (61%) had completed HD multidrug therapy at the time of review, and 73% of these subjects had persistent joint pain requiring steroids or methotrexate for symptomatic control. Chronic arthritis in HD patients is present in a series of US-acquired cases of HD. Arthritis did not resolve with successful treatment of HD in most cases.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29141716      PMCID: PMC5805041          DOI: 10.4269/ajtmh.17-0197

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  29 in total

1.  2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovský; Frederick Wolfe; Gillian Hawker
Journal:  Arthritis Rheum       Date:  2010-09

2.  Subcutaneous nodules and joint deformity in leprosy: case report and review.

Authors:  Diana A Yens; Dimitrios J Asters; Ariel Teitel
Journal:  J Clin Rheumatol       Date:  2003-06       Impact factor: 3.517

3.  Chronic inflammatory joint disease revealing borderline leprosy.

Authors:  Mohamed Imed Miladi; Imed Feki; Zouhir Bahloul; Rachid Jlidi; Chokri Mhiri
Journal:  Joint Bone Spine       Date:  2005-08-01       Impact factor: 4.929

4.  Leprosy initially misdiagnosed as sarcoidosis, adult-onset still disease, or autoinflammatory disease.

Authors:  Sara Simeoni; Antonio Puccetti; Elisa Tinazzi; Orazio Michele Codella; Michele Sorleto; Giuseppe Patuzzo; Chiara Colato; Gianpaolo Tessari; Claudio Lunardi
Journal:  J Clin Rheumatol       Date:  2011-12       Impact factor: 3.517

Review 5.  Minocycline: far beyond an antibiotic.

Authors:  N Garrido-Mesa; A Zarzuelo; J Gálvez
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

6.  Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in leprosy patients with articular involvement.

Authors:  S L E Ribeiro; H L A Pereira; N P Silva; R M S Neves; E I Sato
Journal:  Braz J Med Biol Res       Date:  2008-11       Impact factor: 2.590

7.  Leprosy revealed in a rheumatology clinic: a case series.

Authors:  Shiva Prasad; Ramnath Misra; Amita Aggarwal; Able Lawrence; Nigil Haroon; Anupam Wakhlu; Narendra Krishnani; Vinita Agrawal; Vimal K Paliwal; Sanjeev Jha; Vikas Agarwal
Journal:  Int J Rheum Dis       Date:  2012-08-31       Impact factor: 2.454

8.  Leprosy mimicking common rheumatologic entities: a trial for the clinician in the era of biologics.

Authors:  Deepak Rath; Shrinath Bhargava; Bijit Kumar Kundu
Journal:  Case Rep Rheumatol       Date:  2014-11-06

9.  Incidence of Hansen's Disease--United States, 1994-2011.

Authors:  Leisha Nolen; Dana Haberling; David Scollard; Richard Truman; Alfonso Rodriguez-Lainz; Laura Blum; David Blaney
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-10-31       Impact factor: 17.586

Review 10.  Arthritis and diagnosis of leprosy: a case report and review of the literature.

Authors:  Tania Rita Moreno de Oliveira Fernandes; Juliana Pedrosa Korinfskin; Mariana Mercês Mesquita Espíndola; Lis Moreno de Oliveira Corrêa
Journal:  An Bras Dermatol       Date:  2014 Mar-Apr       Impact factor: 1.896

View more
  4 in total

1.  Cutaneous leprosy in Central Florida man with significant armadillo exposure.

Authors:  Christopher Michael Logas; Kathryn B Holloway
Journal:  BMJ Case Rep       Date:  2019-06-29

2.  Hansen's disease masquerading as rheumatoid arthritis: A case report.

Authors:  Prashant Pant; Oshan Shrestha; Pragyat Singh; Vivek Paudyal; Istiyaque Alam; Prabhat Singh Rajput; Dhan Bahadur Shrestha
Journal:  Clin Case Rep       Date:  2022-05-12

3.  Mycobacterium leprae transmission characteristics during the declining stages of leprosy incidence: A systematic review.

Authors:  Thomas Hambridge; Shri Lak Nanjan Chandran; Annemieke Geluk; Paul Saunderson; Jan Hendrik Richardus
Journal:  PLoS Negl Trop Dis       Date:  2021-05-26

4.  Rheumatoid arthritis-like features in Hansen disease: A case report.

Authors:  Le-Nyu Gao; Bing Zhong; Yong Wang
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.